Immucell Corp (ICCC) Stock Price, Quote & News

Latest News on ICCC

Jan 16, 2025, 4:05 PM EST - 1 day ago

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

Jan 9, 2025, 4:05 PM EST - 8 days ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

Nov 14, 2024, 11:09 AM EST - 2 months ago

ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 2 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 8:30 AM EST - 2 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

Oct 8, 2024, 4:05 PM EDT - 3 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

Aug 14, 2024, 12:18 PM EDT - 5 months ago

ImmuCell Corporation (ICCC) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:05 PM EDT - 5 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024

Aug 7, 2024, 4:05 PM EDT - 5 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024

Jul 9, 2024, 4:05 PM EDT - 6 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024

Jun 5, 2024, 4:05 PM EDT - 8 months ago

ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®

Jun 4, 2024, 4:05 PM EDT - 8 months ago

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

May 15, 2024, 1:48 PM EDT - 8 months ago

ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:05 PM EDT - 8 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024

May 8, 2024, 1:00 PM EDT - 9 months ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024

Apr 9, 2024, 4:05 PM EDT - 10 months ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

Feb 28, 2024, 11:58 AM EST - 11 months ago

ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:05 PM EST - 11 months ago

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Feb 16, 2024, 9:30 AM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Jan 8, 2024, 4:05 PM EST - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

Nov 14, 2023, 2:36 PM EST - 1 year ago

ImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

Nov 7, 2023, 12:15 PM EST - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

Oct 5, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

Aug 29, 2023, 8:00 AM EDT - 1 year ago

ImmuCell Announces Submission of CMC Technical Section to the FDA

Aug 11, 2023, 4:48 PM EDT - 1 year ago

ImmuCell Corporation (ICCC) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

Aug 7, 2023, 12:00 PM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

Jul 11, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023

Jun 28, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Change in Timing of Anticipated FDA Submission

Jun 21, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Appoints Bryan K. Gathagan to Board of Directors

Jun 15, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

May 12, 2023, 10:00 AM EDT - 1 year ago

ImmuCell Corporation (ICCC) Q1 2023 Earnings Call Transcript

May 11, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023

May 4, 2023, 6:30 AM EDT - 1 year ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

Apr 5, 2023, 4:05 PM EDT - 1 year ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023

Feb 22, 2023, 12:50 PM EST - 2 years ago

ImmuCell Corporation (ICCC) Q4 2022 Earnings Call Transcript

Feb 21, 2023, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

Feb 15, 2023, 11:55 AM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

Jan 9, 2023, 4:05 PM EST - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022

Nov 22, 2022, 11:37 AM EST - 2 years ago

ImmuCell Corporation (ICCC) Q3 2022 Earnings Call Transcript

Nov 21, 2022, 4:05 PM EST - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022

Nov 10, 2022, 4:05 PM EST - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022

Oct 5, 2022, 6:30 AM EDT - 2 years ago

ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022

Sep 14, 2022, 5:00 PM EDT - 2 years ago

ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference

Aug 12, 2022, 1:13 PM EDT - 2 years ago

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q2 2022 Results - Earnings Call Transcript

Aug 11, 2022, 4:05 PM EDT - 2 years ago

ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022

Aug 4, 2022, 6:30 AM EDT - 2 years ago

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022

Jul 27, 2022, 8:05 PM EDT - 2 years ago

ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®

Jul 7, 2022, 6:30 AM EDT - 2 years ago

Market Cap	46.61M
Revenue (ttm)	17.47M
Net Income (ttm)	-5.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-33.03%
Debt to Equity Ratio	0.41

Volume	5,600
Avg Vol	16,600
Day's Range	N/A - N/A
Shares Out	8.91M
Stochastic %K	100%
Beta	0.54
Analysts	Strong Buy
Price Target	$14.00